$elv 2020 Q2 10-Q

Concept	2020 Q2	2019 Q2
Revenue	$29.26B	$25.47B
YoY Change	14.91%	10.99%
Cost Of Revenue	$2.225B	$98.00M
YoY Change	2170.41%
Gross Profit	$27.04B	$25.37B
YoY Change	6.59%	10.56%
Gross Profit Margin	92.4%	99.62%
Selling, General & Admin	$4.046B	$3.278B
YoY Change	23.43%	-4.38%
% of Gross Profit	14.96%	12.92%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$286.0M	$297.0M
YoY Change	-3.7%	3.85%
% of Gross Profit	1.06%	1.17%
Operating Expenses	$4.046B	$3.278B
YoY Change	23.43%	-4.38%
Operating Profit	$3.360B	$1.433B
YoY Change	134.47%	-8.08%
Interest Expense	$201.0M	$184.0M
YoY Change	9.24%	-4.17%
% of Operating Profit	5.98%	12.84%
Other Income/Expense, Net
YoY Change
Pretax Income	$3.149B	$1.453B
YoY Change	116.72%	-3.39%
Income Tax	$873.0M	$314.0M
% Of Pretax Income	27.72%	21.61%
Net Earnings	$2.276B	$1.139B
YoY Change	99.82%	8.06%
Net Earnings / Revenue	7.78%	4.47%
Basic Earnings Per Share	$9.02	$4.44
Diluted Earnings Per Share	$8.91	$4.36
COMMON SHARES
Basic Shares Outstanding	252.2M shares	256.7M shares
Diluted Shares Outstanding	255.4M shares	261.0M shares

Concept	2020 Q2	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.05B	$23.20B
YoY Change	20.88%	6.6%
Cash & Equivalents	$6.028B	$4.078B
Short-Term Investments	$22.02B	$19.12B
Other Short-Term Assets	$4.260B	$2.151B
YoY Change	98.05%	-30.75%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$46.76B	$37.81B
YoY Change	23.7%	1.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.427B	$2.837B
YoY Change	20.8%	18.59%
Goodwill	$21.64B	$20.50B
YoY Change	5.57%	0.42%
Intangibles	$9.577B	$8.840B
YoY Change	8.34%	-4.17%
Long-Term Investments	$30.11B	$24.89B
YoY Change	20.95%	5.66%
Other Assets	$1.950B	$1.608B
YoY Change	21.27%	69.19%
Total Long-Term Assets	$41.21B	$38.05B
YoY Change	8.32%	2.84%
TOTAL ASSETS
Total Short-Term Assets	$46.76B	$37.81B
Total Long-Term Assets	$41.21B	$38.05B
Total Assets	$87.98B	$75.85B
YoY Change	15.99%	1.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.257B	$4.028B
YoY Change	30.51%	-32.09%
Accrued Expenses	$1.008B	$699.0M
YoY Change	44.21%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$1.010B
YoY Change	-100.0%	-9.82%
Long-Term Debt Due	$1.603B	$850.0M
YoY Change	88.59%	30.73%
Total Short-Term Liabilities	$28.52B	$23.09B
YoY Change	23.53%	-5.78%
LONG-TERM LIABILITIES
Long-Term Debt	$19.87B	$17.44B
YoY Change	13.98%	-0.45%
Other Long-Term Liabilities	$1.853B	$1.666B
YoY Change	11.22%	55.06%
Total Long-Term Liabilities	$21.73B	$19.10B
YoY Change	13.74%	2.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$28.52B	$23.09B
Total Long-Term Liabilities	$21.73B	$19.10B
Total Liabilities	$53.52B	$45.06B
YoY Change	18.78%	-1.28%
SHAREHOLDERS EQUITY
Retained Earnings	$25.35B	$21.68B
YoY Change	16.91%	9.73%
Common Stock	$3.000M	$3.000M
YoY Change	0.0%	15.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$34.46B	$30.79B
YoY Change
Total Liabilities & Shareholders Equity	$87.98B	$75.85B
YoY Change	15.99%	1.99%

Concept	2020 Q2	2019 Q2
OPERATING ACTIVITIES
Net Income	$2.276B	$1.139B
YoY Change	99.82%	8.06%
Depreciation, Depletion And Amortization	$286.0M	$297.0M
YoY Change	-3.7%	3.85%
Cash From Operating Activities	$5.510B	$1.437B
YoY Change	283.44%	165.13%
INVESTING ACTIVITIES
Capital Expenditures	-$233.0M	-$221.0M
YoY Change	5.43%	-29.84%
Acquisitions
YoY Change
Other Investing Activities	-$4.701B	-$944.0M
YoY Change	397.99%	103.45%
Cash From Investing Activities	-$4.934B	-$1.165B
YoY Change	323.52%	49.74%
FINANCING ACTIVITIES
Cash Dividend Paid	$242.0M	$206.0M
YoY Change	17.48%	5.1%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	105.0M	-677.0M
YoY Change	-115.51%	-334.26%
NET CHANGE
Cash From Operating Activities	5.510B	1.437B
Cash From Investing Activities	-4.934B	-1.165B
Cash From Financing Activities	105.0M	-677.0M
Net Change In Cash	681.0M	-405.0M
YoY Change	-268.15%	-864.15%
FREE CASH FLOW
Cash From Operating Activities	$5.510B	$1.437B
Capital Expenditures	-$233.0M	-$221.0M
Free Cash Flow	$5.743B	$1.658B
YoY Change	246.38%	93.47%

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q4	antm	Available For Sale Securities Debt Maturities Amortized Cost Noncurrent AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostNoncurrent	487000000	USD
CY2020Q2	antm	Available For Sale Securities Debt Maturities Amortized Cost Noncurrent AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostNoncurrent	491000000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	2000000	USD
CY2019Q2	antm	Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense	-1000000	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	0	USD
	antm	Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense	-2000000	USD
CY2020Q2	antm	Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense	-4000000	USD
	antm	Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense	-7000000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	-4000000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	5000000	USD
CY2019Q2	antm	Taxexpensebenefitofnoncreditimpairmentonavailableforsalesecuritiesrecognizedinothercomprehensiveincomeloss Taxexpensebenefitofnoncreditimpairmentonavailableforsalesecuritiesrecognizedinothercomprehensiveincomeloss	0	USD
	antm	Taxexpensebenefitofnoncreditimpairmentonavailableforsalesecuritiesrecognizedinothercomprehensiveincomeloss Taxexpensebenefitofnoncreditimpairmentonavailableforsalesecuritiesrecognizedinothercomprehensiveincomeloss	0	USD
CY2020Q2	antm	Taxexpensebenefitofnoncreditimpairmentonavailableforsalesecuritiesrecognizedinothercomprehensiveincomeloss Taxexpensebenefitofnoncreditimpairmentonavailableforsalesecuritiesrecognizedinothercomprehensiveincomeloss	-2000000	USD
	antm	Taxexpensebenefitofnoncreditimpairmentonavailableforsalesecuritiesrecognizedinothercomprehensiveincomeloss Taxexpensebenefitofnoncreditimpairmentonavailableforsalesecuritiesrecognizedinothercomprehensiveincomeloss	7000000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Entity Central Index Key EntityCentralIndexKey	0001156039
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	19021000000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	21358000000	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	252922161	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	252122363	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	252922161	shares
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	252122363	shares
CY2019Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	-71000000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	-170000000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	-238000000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	-23000000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	0	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	0	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	0	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	0	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax	1000000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-73000000	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-174000000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-241000000	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-30000000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	0	USD
CY2020Q2	us-gaap	Other Receivables OtherReceivables	3072000000	USD
CY2019Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	5014000000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	-1000000	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	-2000000	USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-16751
	dei	Entity Registrant Name EntityRegistrantName	ANTHEM, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	IN
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	35-2145715
	dei	Entity Address Address Line1 EntityAddressAddressLine1	220 Virginia Avenue
	dei	Entity Address City Or Town EntityAddressCityOrTown	Indianapolis
	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46204
	dei	City Area Code CityAreaCode	800
	dei	Local Phone Number LocalPhoneNumber	331-1476
	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value
	dei	Trading Symbol TradingSymbol	ANTM
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	251506458	shares
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6028000000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4937000000	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	22018000000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	19676000000	USD
CY2020Q2	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	3470000000	USD
CY2019Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	1009000000	USD
CY2020Q2	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	5456000000	USD
CY2020Q2	antm	Self Funded Receivables Net SelfFundedReceivablesNet	2460000000	USD
CY2019Q4	antm	Self Funded Receivables Net SelfFundedReceivablesNet	2570000000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23532000000	USD
CY2020Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2497000000	USD
CY2020Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7252000000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4127000000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	28522000000	USD
CY2019Q4	us-gaap	Other Receivables OtherReceivables	2807000000	USD
CY2020Q2	us-gaap	Other Assets Current OtherAssetsCurrent	4260000000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3020000000	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	46764000000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	39033000000	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	520000000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	505000000	USD
CY2020Q2	us-gaap	Other Long Term Investments OtherLongTermInvestments	4097000000	USD
CY2019Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	4258000000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3427000000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3133000000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	21641000000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	20500000000	USD
CY2020Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9577000000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8674000000	USD
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1950000000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1350000000	USD
CY2020Q2	us-gaap	Assets Assets	87976000000	USD
CY2019Q4	us-gaap	Assets Assets	77453000000	USD
CY2020Q2	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	9878000000	USD
CY2019Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	8842000000	USD
CY2020Q2	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	3586000000	USD
CY2019Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	3050000000	USD
CY2020Q2	us-gaap	Unearned Premiums UnearnedPremiums	946000000	USD
CY2019Q4	us-gaap	Unearned Premiums UnearnedPremiums	1017000000	USD
CY2020Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5257000000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4198000000	USD
CY2020Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	0	USD
CY2019Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	700000000	USD
CY2020Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	1603000000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1598000000	USD
CY2020Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19873000000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	17787000000	USD
CY2020Q2	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	776000000	USD
CY2019Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	759000000	USD
CY2019Q2	us-gaap	Other Income OtherIncome	1532000000	USD
	us-gaap	Other Income OtherIncome	3130000000	USD
	us-gaap	Other Income OtherIncome	3077000000	USD
	us-gaap	Net Investment Income NetInvestmentIncome	311000000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2227000000	USD
	antm	Product Revenue ProductRevenue	4887000000	USD
	us-gaap	Net Investment Income NetInvestmentIncome	495000000	USD
	antm	Product Revenue ProductRevenue	144000000	USD
CY2020Q2	us-gaap	Other Income OtherIncome	1543000000	USD
CY2019Q2	us-gaap	Net Investment Income NetInvestmentIncome	285000000	USD
CY2020Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1853000000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1420000000	USD
CY2020Q2	us-gaap	Liabilities Liabilities	53521000000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	45725000000	USD
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	3000000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	3000000	USD
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9360000000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9448000000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	25346000000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	22573000000	USD
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-254000000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-296000000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	34455000000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	31728000000	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	87976000000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	77453000000	USD
CY2020Q2	us-gaap	Premiums Earned Net PremiumsEarnedNet	25092000000	USD
CY2019Q2	us-gaap	Premiums Earned Net PremiumsEarnedNet	23501000000	USD
	us-gaap	Premiums Earned Net PremiumsEarnedNet	50609000000	USD
	us-gaap	Premiums Earned Net PremiumsEarnedNet	46344000000	USD
CY2020Q2	antm	Product Revenue ProductRevenue	2543000000	USD
CY2019Q2	antm	Product Revenue ProductRevenue	144000000	USD
CY2020Q2	antm	Operating Revenue OperatingRevenue	29178000000	USD
CY2019Q2	antm	Operating Revenue OperatingRevenue	25177000000	USD
	antm	Operating Revenue OperatingRevenue	58626000000	USD
	antm	Operating Revenue OperatingRevenue	49565000000	USD
CY2020Q2	us-gaap	Net Investment Income NetInvestmentIncome	57000000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6444000000	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	201000000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	172000000	USD
CY2019Q2	us-gaap	Interest Expense InterestExpense	184000000	USD
CY2020Q2	antm	Netrealizedlossesgainsonfinancialinstruments Netrealizedlossesgainsonfinancialinstruments	18000000	USD
CY2019Q2	antm	Netrealizedlossesgainsonfinancialinstruments Netrealizedlossesgainsonfinancialinstruments	11000000	USD
	antm	Netrealizedlossesgainsonfinancialinstruments Netrealizedlossesgainsonfinancialinstruments	-6000000	USD
	antm	Netrealizedlossesgainsonfinancialinstruments Netrealizedlossesgainsonfinancialinstruments	89000000	USD
CY2020Q2	antm	Impairmentlossesreversalsoninvestments Impairmentlossesreversalsoninvestments	-6000000	USD
CY2019Q2	antm	Impairmentlossesreversalsoninvestments Impairmentlossesreversalsoninvestments	9000000	USD
	antm	Impairmentlossesreversalsoninvestments Impairmentlossesreversalsoninvestments	95000000	USD
	antm	Impairmentlossesreversalsoninvestments Impairmentlossesreversalsoninvestments	22000000	USD
CY2020Q2	antm	Noncreditcomponentofimpairmentlossesoninvestmentsrecognizedinothercomprehensiveincomebeforetax Noncreditcomponentofimpairmentlossesoninvestmentsrecognizedinothercomprehensiveincomebeforetax	-5000000	USD
CY2019Q2	antm	Noncreditcomponentofimpairmentlossesoninvestmentsrecognizedinothercomprehensiveincomebeforetax Noncreditcomponentofimpairmentlossesoninvestmentsrecognizedinothercomprehensiveincomebeforetax	-2000000	USD
	antm	Noncreditcomponentofimpairmentlossesoninvestmentsrecognizedinothercomprehensiveincomebeforetax Noncreditcomponentofimpairmentlossesoninvestmentsrecognizedinothercomprehensiveincomebeforetax	-49000000	USD
	antm	Noncreditcomponentofimpairmentlossesoninvestmentsrecognizedinothercomprehensiveincomebeforetax Noncreditcomponentofimpairmentlossesoninvestmentsrecognizedinothercomprehensiveincomebeforetax	-5000000	USD
CY2020Q2	antm	Impairmentlossesreversalsrecognizedinearnings Impairmentlossesreversalsrecognizedinearnings	-11000000	USD
CY2019Q2	antm	Impairmentlossesreversalsrecognizedinearnings Impairmentlossesreversalsrecognizedinearnings	7000000	USD
	antm	Impairmentlossesreversalsrecognizedinearnings Impairmentlossesreversalsrecognizedinearnings	46000000	USD
	antm	Impairmentlossesreversalsrecognizedinearnings Impairmentlossesreversalsrecognizedinearnings	17000000	USD
CY2020Q2	us-gaap	Revenues Revenues	29264000000	USD
CY2019Q2	us-gaap	Revenues Revenues	25466000000	USD
	us-gaap	Revenues Revenues	58885000000	USD
	us-gaap	Revenues Revenues	50132000000	USD
CY2020Q2	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	19547000000	USD
CY2019Q2	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	20368000000	USD
	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	41036000000	USD
	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	39650000000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2225000000	USD
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	98000000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4209000000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	98000000	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4046000000	USD
CY2019Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3278000000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7827000000	USD
	us-gaap	Interest Expense InterestExpense	395000000	USD
	us-gaap	Interest Expense InterestExpense	371000000	USD
CY2020Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	93000000	USD
CY2019Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	85000000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	176000000	USD
CY2020Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3000000	USD
CY2019Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4000000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1000000	USD
CY2020Q2	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	26115000000	USD
CY2019Q2	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	24013000000	USD
	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	53647000000	USD
	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	46734000000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3149000000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1453000000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5238000000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3398000000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	873000000	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	314000000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1439000000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	708000000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	2276000000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	1139000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	3799000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	2690000000	USD
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	9.02
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.44
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	15.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	10.47
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	8.91
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.36
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	14.85
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	10.28
CY2020Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.95
CY2019Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.80
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.90
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.60
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	2276000000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	1139000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	3799000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	2690000000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	730000000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	238000000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	41000000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	595000000	USD
CY2020Q2	antm	Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax	10000000	USD
CY2019Q2	antm	Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax	-1000000	USD
	antm	Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax	-22000000	USD
	antm	Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax	-1000000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	3000000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	6000000	USD
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	3000000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-10000000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-3000000	USD
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-17000000	USD
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-6000000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1000000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	754000000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	240000000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	42000000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	603000000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3030000000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1379000000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3841000000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3293000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	3799000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	2690000000	USD
	antm	Netrealizedlossesgainsonfinancialinstruments Netrealizedlossesgainsonfinancialinstruments	-6000000	USD
	antm	Netrealizedlossesgainsonfinancialinstruments Netrealizedlossesgainsonfinancialinstruments	89000000	USD
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	556000000	USD
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	586000000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	60000000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	79000000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	134000000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	140000000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	313000000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	589000000	USD
	us-gaap	Increase Decrease In Trading Securities IncreaseDecreaseInTradingSecurities	-24000000	USD
	us-gaap	Increase Decrease In Trading Securities IncreaseDecreaseInTradingSecurities	28000000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	486000000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	258000000	USD
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	1024000000	USD
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	1251000000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-110000000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2000000	USD
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	1868000000	USD
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-383000000	USD
	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	1313000000	USD
	us-gaap	Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable	-286000000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-150000000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	44000000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8025000000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3067000000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	11135000000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	11113000000	USD
	antm	Proceedsfromsaleofequityandfixedmaturitysecurities Proceedsfromsaleofequityandfixedmaturitysecurities	4724000000	USD
	antm	Proceedsfromsaleofequityandfixedmaturitysecurities Proceedsfromsaleofequityandfixedmaturitysecurities	8835000000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1836000000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	894000000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1906000000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	437000000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	455000000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	800000000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-22000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7718000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1817000000	USD
	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	-400000000	USD
	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	203000000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	2484000000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	155000000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	73000000	USD
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	820000000	USD
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	4805000000	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1520000000	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	4940000000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	584000000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	752000000	USD
	us-gaap	Payments Of Dividends PaymentsOfDividends	482000000	USD
	us-gaap	Payments Of Dividends PaymentsOfDividends	412000000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	92000000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	100000000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	111000000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	80000000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	640000000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	43000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	784000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1106000000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1091000000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	144000000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4937000000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3934000000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6028000000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4078000000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	31728000000	USD
CY2019Q4	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	-35000000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1 StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	31693000000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	1523000000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-712000000	USD
CY2020Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	529000000	USD
CY2020Q1	us-gaap	Dividends Common Stock DividendsCommonStock	243000000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3000000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-42000000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	31693000000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	2276000000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	754000000	USD
CY2020Q2	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	55000000	USD
CY2020Q2	us-gaap	Dividends Common Stock DividendsCommonStock	244000000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	113000000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-82000000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	34455000000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	28541000000	USD
CY2018Q4	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	26000000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1 StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1	28567000000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	1551000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	363000000	USD
CY2019Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	294000000	USD
CY2019Q1	us-gaap	Dividends Common Stock DividendsCommonStock	206000000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	69000000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-52000000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	29998000000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	1139000000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	240000000	USD
CY2019Q2	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	458000000	USD
CY2019Q2	us-gaap	Dividends Common Stock DividendsCommonStock	208000000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	91000000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-9000000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	30793000000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">References to the terms “we,” “our,” “us” or “Anthem” used throughout these Notes to Consolidated Financial Statements refer to Anthem, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia, unless the context otherwise requires.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are one of the largest health benefits companies in the United States in terms of medical membership, serving greater than </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>42</span></span><span style="font-family:inherit;font-size:10pt;"> million </span><span style="font-family:inherit;font-size:10pt;">medical members through our affiliated health plans as of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">. We offer a broad spectrum of network-based managed care plans to Large Group, Small Group, Individual, Medicaid and Medicare markets. Our managed care plans include: Preferred Provider Organizations, or PPOs; Health Maintenance Organizations, or HMOs; Point-of-Service plans; traditional indemnity plans and other hybrid plans, including Consumer-Driven Health Plans; and hospital only and limited benefit products. In addition, we provide a broad array of managed care services to self-funded customers, including claims processing, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services. We provide an array of specialty and other insurance products and services such as pharmacy benefits management, or PBM, dental, vision, life and disability insurance benefits, radiology benefit management and analytics-driven personal healthcare. We also provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits, or FEHB, Program.</span></div><span style="font-family:inherit;font-size:10pt;">We are an independent licensee of the Blue Cross and Blue Shield Association, or BCBSA, an association of independent health benefit plans. </span><span style="font-family:inherit;font-size:10pt;">We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield, or BCBS, licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous </span><span style="font-family:inherit;font-size:10pt;">states across the country as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, Optimum HealthCare, Simply Healthcare, and/or Unicare. Also, in the second quarter of 2019, we began providing</span><span style="font-family:inherit;font-size:10pt;"> PBM services through our IngenioRx subsidiary. We are licensed to conduct insurance operations in all </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>50</span></span> states and the District of Columbia through our subsidiaries.
CY2020Q2	antm	Number Of Medical Members Served NumberOfMedicalMembersServed	42000000	medical_member
CY2020Q2	antm	Number Of Counties In State Of Kansas Company Does Not Serve NumberOfCountiesInStateOfKansasCompanyDoesNotServe	30	county
CY2020Q2	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	50	states
CY2020Q2	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	231000000	USD
CY2019Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	215000000	USD
	antm	Securities Lending Transactions Initial Collateral Percentage Value SecuritiesLendingTransactionsInitialCollateralPercentageValue	1.02
CY2020Q2	us-gaap	Premiums Receivable Allowance For Doubtful Accounts PremiumsReceivableAllowanceForDoubtfulAccounts	259000000	USD
CY2019Q4	us-gaap	Premiums Receivable Allowance For Doubtful Accounts PremiumsReceivableAllowanceForDoubtfulAccounts	237000000	USD
CY2020Q2	antm	Selffunded Receivables Allowance For Doubtful Accounts SelffundedReceivablesAllowanceForDoubtfulAccounts	52000000	USD
CY2019Q4	antm	Selffunded Receivables Allowance For Doubtful Accounts SelffundedReceivablesAllowanceForDoubtfulAccounts	46000000	USD
CY2020Q2	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	321000000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	242000000	USD
CY2020Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	-35000000	USD
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Guidance Not Yet Adopted: </span><span style="font-family:inherit;font-size:10pt;">In March 2020, the FASB issued Accounting Standards Update No. 2020-04, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="font-family:inherit;font-size:10pt;">, or ASU 2020-04. ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate, or LIBOR, or another reference rate expected to be discontinued because of the reference rate reform. The provisions must be applied at a Topic, Subtopic, or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. The provisions within ASU 2020-04 are available until December 31, 2022, when the reference rate replacement activity is expected to have been completed. We are currently evaluating the provisions within ASU 2020-04.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued Accounting Standards Update No. 2019-12, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,</span><span style="font-family:inherit;font-size:10pt;"> or ASU 2019-12. The amendments in ASU 2019-12 remove certain exceptions to the general principles in Accounting Standards Codification Topic 740. The amendments also clarify and amend existing guidance to improve consistent application. The amendments are effective for our annual reporting periods beginning after December 15, 2020, with early adoption permitted. The transition method (retrospective, modified retrospective, or prospective basis) related to the amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis. We are currently evaluating the effects the adoption of ASU 2019-12 will have on our consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued Accounting Standards Update No. 2018-14, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation—Retirement Benefits - Defined Benefit Plans—General (Subtopic 715-20): Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans</span><span style="font-family:inherit;font-size:10pt;">, or ASU 2018-14. The amendments in ASU 2018-14 eliminate, add, and modify certain disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The amendments are effective for our annual reporting periods beginning after December 15, 2020, with early adoption permitted. The guidance is to be applied on a retrospective basis to all periods presented. We are currently evaluating the effects the adoption of ASU 2018-14 will have on our disclosures.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued Accounting Standards Update No. 2018-12,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts, </span><span style="font-family:inherit;font-size:10pt;">or ASU 2018-12. The amendments in ASU 2018-12 make changes to a variety of areas to simplify or improve the existing recognition, measurement, presentation and disclosure requirements for long-duration contracts issued by an insurance entity. The amendments require insurers to annually review the assumptions they make about their policyholders and update the liabilities for future policy benefits if the assumptions change. The amendments also simplify the amortization of deferred contract acquisition costs and add new disclosure requirements about the assumptions insurers use to measure their liabilities and how they may affect future cash flows. The amendments in ASU 2018-12 will be effective for our interim and annual reporting periods beginning after December 15, 2021. The amendments related to the liability for future policy benefits for traditional and limited-payment contracts and deferred acquisition costs are to be applied to contracts in force as of the beginning of the earliest period presented, with an option to apply such amendments retrospectively with a cumulative-effect adjustment to the opening balance of retained earnings as of the earliest period presented. The amendments for market risk benefits are to be applied retrospectively. We are currently evaluating the effects the adoption of ASU 2018-12 will have on our consolidated financial position, results of operations, cash flows, and related disclosures.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no other new accounting pronouncements that were issued or became effective since the issuance of our </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position, results of operations or cash flows.</span></div>
CY2020Q2	antm	Netaccumulatedunrealizedgainslossesonavailableforsalefixedmaturitysecurities Netaccumulatedunrealizedgainslossesonavailableforsalefixedmaturitysecurities	713000000	USD
CY2019Q4	antm	Netaccumulatedunrealizedgainslossesonavailableforsalefixedmaturitysecurities Netaccumulatedunrealizedgainslossesonavailableforsalefixedmaturitysecurities	673000000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	51000000	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	10000000	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	-8000000	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	-29000000	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	24000000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	61000000	USD
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	-8000000	USD
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	-29000000	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	24000000	USD
CY2020Q2	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	2618000000	USD
CY2019Q2	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	1986000000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	4549000000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	3454000000	USD
CY2020Q2	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	37000000	USD
CY2019Q2	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	22000000	USD
	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	80000000	USD
	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	40000000	USD
CY2020Q2	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	50000000	USD
CY2019Q2	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	17000000	USD
	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	70000000	USD
	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	34000000	USD
CY2020Q2	antm	Equity Securities EquitySecurities	3470000000	USD
CY2019Q4	antm	Equity Securities EquitySecurities	1009000000	USD
CY2020Q2	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	182000000	USD
CY2019Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	173000000	USD
CY2020Q2	us-gaap	Securities Loaned Fair Value Of Collateral SecuritiesLoanedFairValueOfCollateral	1114000000	USD
CY2019Q4	us-gaap	Securities Loaned Fair Value Of Collateral SecuritiesLoanedFairValueOfCollateral	351000000	USD
	antm	Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan	1.02
CY2019	antm	Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan	1.03
CY2020Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	3809000000	USD
CY2020Q2	us-gaap	Securities Held As Collateral At Fair Value SecuritiesHeldAsCollateralAtFairValue	1114000000	USD
CY2020Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	30981000000	USD
CY2020Q2	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	0	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	2015000000	USD
CY2019Q4	us-gaap	Securities Held As Collateral At Fair Value SecuritiesHeldAsCollateralAtFairValue	353000000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	23581000000	USD
CY2019Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	1000000	USD
CY2020Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	405000000	USD
CY2020Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-9000000	USD
CY2020Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss	-7000000	USD
CY2020Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	17000000	USD
CY2020Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales	14000000	USD
CY2020Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements	9000000	USD
CY2020Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0	USD
CY2020Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0	USD
CY2020Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	383000000	USD
CY2020Q2	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-10000000	USD
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	614000000	USD
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-1000000	USD
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss	0	USD
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	44000000	USD
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales	9000000	USD
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements	21000000	USD
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0	USD
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	11000000	USD
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	616000000	USD
CY2019Q2	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-2000000	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	397000000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-17000000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss	-17000000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	54000000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales	26000000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements	21000000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	13000000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0	USD
CY2020Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	383000000	USD
	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-17000000	USD
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	623000000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-4000000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss	2000000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	86000000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales	31000000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements	43000000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	3000000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	20000000	USD
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	616000000	USD
	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	0	USD
CY2020Q2	us-gaap	Other Long Term Investments OtherLongTermInvestments	4097000000	USD
CY2020Q2	us-gaap	Notes Payable NotesPayable	24273000000	USD
CY2020Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	426000000	USD
CY2019Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	4258000000	USD
CY2019Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	700000000	USD
CY2019Q4	us-gaap	Commercial Paper CommercialPaper	400000000	USD
CY2019Q4	us-gaap	Notes Payable NotesPayable	20470000000	USD
CY2019Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	904000000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	873000000	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	314000000	USD
CY2020Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.277
CY2019Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.216
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1439000000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	708000000	USD
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.275
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.208
CY2020Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	978000000	USD
CY2019Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	335000000	USD
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	3000000	USD
	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	0	USD
	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div style="line-height:120%;padding-bottom:4px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Commercial</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">& Specialty</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Government</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross medical claims payable, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,608</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,647</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net medical claims payable, beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,025</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,589</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,614</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Business combinations and purchase adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>198</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>339</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net incurred medical claims:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,318</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,162</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>498</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,978</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior periods redundancies</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(374</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(326</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(700</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net incurred medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,944</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,836</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>498</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net payments attributable to:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current period medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,014</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,115</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>496</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,625</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior periods medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,218</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,823</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,041</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,938</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>496</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,666</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net medical claims payable, end of period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,737</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,628</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,565</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, end of period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross medical claims payable, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,799</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,656</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>200</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,655</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Activity in the Other segment resulted from our acquisition of Beacon.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the total of net incurred but not reported liabilities plus expected development on reported claims for the Commercial & Specialty Business was </span><span style="font-family:inherit;font-size:10pt;"><span>$74</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$358</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2,305</span></span><span style="font-family:inherit;font-size:10pt;"> for the claim years 2018 and prior, 2019 and 2020, respectively.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the total of net incurred but not reported liabilities plus expected development on reported claims for the Government Business was </span><span style="font-family:inherit;font-size:10pt;"><span>$80</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$360</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$6,188</span></span><span style="font-family:inherit;font-size:10pt;"> for the claim years 2018 and prior, 2019 and 2020, respectively.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the total of net incurred but not reported liabilities plus expected development on reported claims for Other was </span><span style="font-family:inherit;font-size:10pt;"><span>$0</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$200</span></span><span style="font-family:inherit;font-size:10pt;"> for the claim years 2018 and prior, 2019 and 2020, respectively.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Commercial</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">& Specialty</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Government</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross medical claims payable, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,586</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,680</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,266</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net medical claims payable, beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,576</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,656</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net incurred medical claims:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,460</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,777</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,237</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior periods redundancies</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(182</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(232</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(414</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net incurred medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,545</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,823</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net payments attributable to:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current period medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,928</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,439</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,367</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior periods medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,081</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,101</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,182</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,009</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,540</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,549</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net medical claims payable, end of period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,845</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,661</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,506</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, end of period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross medical claims payable, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,859</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,690</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,549</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div>
CY2019Q4	antm	Short Duration Contract Liability For Claims Adjustment Expense ShortDurationContractLiabilityForClaimsAdjustmentExpense	8647000000	USD
CY2019Q4	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	33000000	USD
CY2019Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	8614000000	USD
CY2020Q2	antm	Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments	339000000	USD
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	39978000000	USD
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	700000000	USD
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	39278000000	USD

CY2019Q4

antm

Available For Sale Securities Debt Maturities Amortized Cost Noncurrent

AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostNoncurrent

487000000

USD

CY2020Q2

antm

Available For Sale Securities Debt Maturities Amortized Cost Noncurrent

AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostNoncurrent

491000000

USD

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax

2000000

USD

CY2019Q2

antm

Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense

OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense

-1000000

USD

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax

0

USD

antm

Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense

OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense

-2000000

USD

CY2020Q2

antm

Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense

OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense

-4000000

USD

antm

Other Net Change In Unrecognized Periodic Benefit Costs For Defined Benefit Pension And Postretirement Benefit Plans Tax Benefit Expense

OtherNetChangeInUnrecognizedPeriodicBenefitCostsForDefinedBenefitPensionAndPostretirementBenefitPlansTaxBenefitExpense

-7000000

USD

CY2020Q2

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax

-4000000

USD

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax

5000000

USD

CY2019Q2

antm

Taxexpensebenefitofnoncreditimpairmentonavailableforsalesecuritiesrecognizedinothercomprehensiveincomeloss

0

USD

antm

Taxexpensebenefitofnoncreditimpairmentonavailableforsalesecuritiesrecognizedinothercomprehensiveincomeloss

0

USD

CY2020Q2

antm

Taxexpensebenefitofnoncreditimpairmentonavailableforsalesecuritiesrecognizedinothercomprehensiveincomeloss

-2000000

USD

antm

Taxexpensebenefitofnoncreditimpairmentonavailableforsalesecuritiesrecognizedinothercomprehensiveincomeloss

7000000

USD

dei

Amendment Flag

AmendmentFlag

false

dei

Current Fiscal Year End Date

CurrentFiscalYearEndDate

--12-31

dei

Document Fiscal Period Focus

DocumentFiscalPeriodFocus

Q2

dei

Document Fiscal Year Focus

DocumentFiscalYearFocus

2020

dei

Entity Central Index Key

EntityCentralIndexKey

0001156039

CY2019Q4

us-gaap

Available For Sale Debt Securities Amortized Cost Basis

AvailableForSaleDebtSecuritiesAmortizedCostBasis

19021000000

USD

CY2020Q2

us-gaap

Available For Sale Debt Securities Amortized Cost Basis

AvailableForSaleDebtSecuritiesAmortizedCostBasis

21358000000

USD

CY2019Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2020Q2

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.01

CY2019Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

900000000

shares

CY2020Q2

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

900000000

shares

CY2019Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

252922161

shares

CY2020Q2

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

252122363

shares

CY2019Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

252922161

shares

CY2020Q2

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

252122363

shares

CY2019Q2

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax

-71000000

USD

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax

-170000000

USD

CY2020Q2

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax

-238000000

USD

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax

-23000000

USD

CY2019Q2

us-gaap

Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax

OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

0

USD

us-gaap

Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax

OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

0

USD

CY2020Q2

us-gaap

Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax

OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

0

USD

us-gaap

Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax

OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

0

USD

CY2019Q2

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax

1000000

USD

CY2019Q2

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

-73000000

USD

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

-174000000

USD

CY2020Q2

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

-241000000

USD

us-gaap

Other Comprehensive Income Loss Tax

OtherComprehensiveIncomeLossTax

-30000000

USD

CY2019Q2

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax

0

USD

CY2020Q2

us-gaap

Other Receivables

OtherReceivables

3072000000

USD

CY2019Q4

us-gaap

Premiums Receivable At Carrying Value

PremiumsReceivableAtCarryingValue

5014000000

USD

CY2020Q2

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax

-1000000

USD

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax

-2000000

USD

CY2019Q4

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0

CY2020Q2

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0

CY2019Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

100000000

shares

CY2020Q2

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

100000000

shares

CY2019Q4

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2020Q2

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2019Q4

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2020Q2

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

dei

Document Type

DocumentType

10-Q

dei

Document Quarterly Report

DocumentQuarterlyReport

true

dei

Document Period End Date

DocumentPeriodEndDate

2020-06-30

dei

Document Transition Report

DocumentTransitionReport

false

dei

Entity File Number

EntityFileNumber

001-16751

dei

Entity Registrant Name

EntityRegistrantName

ANTHEM, INC.

dei

Entity Incorporation State Country Code

EntityIncorporationStateCountryCode

IN

dei

Entity Tax Identification Number

EntityTaxIdentificationNumber

35-2145715

dei

Entity Address Address Line1

EntityAddressAddressLine1

220 Virginia Avenue

dei

Entity Address City Or Town

EntityAddressCityOrTown

Indianapolis

dei

Entity Address State Or Province

EntityAddressStateOrProvince

IN

dei

Entity Address Postal Zip Code

EntityAddressPostalZipCode

46204

dei

City Area Code

CityAreaCode

800

dei

Local Phone Number

LocalPhoneNumber

331-1476

dei

Security12b Title

Security12bTitle

Common Stock, $0.01 par value

dei

Trading Symbol

TradingSymbol

ANTM

dei

Security Exchange Name

SecurityExchangeName

NYSE

dei

Entity Current Reporting Status

EntityCurrentReportingStatus

Yes

dei

Entity Interactive Data Current

EntityInteractiveDataCurrent

Yes

dei

Entity Filer Category

EntityFilerCategory

Large Accelerated Filer

dei

Entity Small Business

EntitySmallBusiness

false

dei

Entity Emerging Growth Company

EntityEmergingGrowthCompany

false

dei

Entity Shell Company

EntityShellCompany

false

CY2020Q3

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

251506458

shares

CY2020Q2

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

6028000000

USD

CY2019Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

4937000000

USD

CY2020Q2

us-gaap

Available For Sale Securities Debt Securities Current

AvailableForSaleSecuritiesDebtSecuritiesCurrent

22018000000

USD

CY2019Q4

us-gaap

Available For Sale Securities Debt Securities Current

AvailableForSaleSecuritiesDebtSecuritiesCurrent

19676000000

USD

CY2020Q2

us-gaap

Equity Securities Fv Ni

EquitySecuritiesFvNi

3470000000

USD

CY2019Q4

us-gaap

Equity Securities Fv Ni

EquitySecuritiesFvNi

1009000000

USD

CY2020Q2

us-gaap

Premiums Receivable At Carrying Value

PremiumsReceivableAtCarryingValue

5456000000

USD

CY2020Q2

antm

Self Funded Receivables Net

SelfFundedReceivablesNet

2460000000

USD

CY2019Q4

antm

Self Funded Receivables Net

SelfFundedReceivablesNet

2570000000

USD

CY2019Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

23532000000

USD

CY2020Q2

us-gaap

Deferred Income Tax Liabilities Net

DeferredIncomeTaxLiabilitiesNet

2497000000

USD

CY2020Q2

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

7252000000

USD

CY2019Q4

us-gaap

Other Liabilities Current

OtherLiabilitiesCurrent

4127000000

USD

CY2020Q2

us-gaap

Liabilities Current

LiabilitiesCurrent

28522000000

USD

CY2019Q4

us-gaap

Other Receivables

OtherReceivables

2807000000

USD

CY2020Q2

us-gaap

Other Assets Current

OtherAssetsCurrent

4260000000

USD

CY2019Q4

us-gaap

Other Assets Current

OtherAssetsCurrent

3020000000

USD

CY2020Q2

us-gaap

Assets Current

AssetsCurrent

46764000000

USD

CY2019Q4

us-gaap

Assets Current

AssetsCurrent

39033000000

USD

CY2020Q2

us-gaap

Available For Sale Securities Debt Securities Noncurrent

AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

520000000

USD

CY2019Q4

us-gaap

Available For Sale Securities Debt Securities Noncurrent

AvailableForSaleSecuritiesDebtSecuritiesNoncurrent

505000000

USD

CY2020Q2

us-gaap

Other Long Term Investments

OtherLongTermInvestments

4097000000

USD

CY2019Q4

us-gaap

Other Long Term Investments

OtherLongTermInvestments

4258000000

USD

CY2020Q2

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

3427000000

USD

CY2019Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

3133000000

USD

CY2020Q2

us-gaap

Goodwill

21641000000

USD

CY2019Q4

us-gaap

Goodwill

20500000000

USD

CY2020Q2

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

9577000000

USD

CY2019Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

8674000000

USD

CY2020Q2

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

1950000000

USD

CY2019Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

1350000000

USD

CY2020Q2

us-gaap

Assets

87976000000

USD

CY2019Q4

us-gaap

Assets

77453000000

USD

CY2020Q2

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

9878000000

USD

CY2019Q4

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

8842000000

USD

CY2020Q2

us-gaap

Other Policyholder Funds

OtherPolicyholderFunds

3586000000

USD

CY2019Q4

us-gaap

Other Policyholder Funds

OtherPolicyholderFunds

3050000000

USD

CY2020Q2

us-gaap

Unearned Premiums

UnearnedPremiums

946000000

USD

CY2019Q4

us-gaap

Unearned Premiums

UnearnedPremiums

1017000000

USD

CY2020Q2

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

5257000000

USD

CY2019Q4

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

4198000000

USD

CY2020Q2

us-gaap

Short Term Borrowings

ShortTermBorrowings

0

USD

CY2019Q4

us-gaap

Short Term Borrowings

ShortTermBorrowings

700000000

USD

CY2020Q2

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1603000000

USD

CY2019Q4

us-gaap

Long Term Debt Current

LongTermDebtCurrent

1598000000

USD

CY2020Q2

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

19873000000

USD

CY2019Q4

us-gaap

Long Term Debt Noncurrent

LongTermDebtNoncurrent

17787000000

USD

CY2020Q2

us-gaap

Liability For Future Policy Benefits

LiabilityForFuturePolicyBenefits

776000000

USD

CY2019Q4

us-gaap

Liability For Future Policy Benefits

LiabilityForFuturePolicyBenefits

759000000

USD

CY2019Q2

us-gaap

Other Income

OtherIncome

1532000000

USD

us-gaap

Other Income

OtherIncome

3130000000

USD

us-gaap

Other Income

OtherIncome

3077000000

USD

us-gaap

Net Investment Income

NetInvestmentIncome

311000000

USD

CY2019Q4

us-gaap

Deferred Income Tax Liabilities Net

DeferredIncomeTaxLiabilitiesNet

2227000000

USD

antm

Product Revenue

ProductRevenue

4887000000

USD

us-gaap

Net Investment Income

NetInvestmentIncome

495000000

USD

antm

Product Revenue

ProductRevenue

144000000

USD

CY2020Q2

us-gaap

Other Income

OtherIncome

1543000000

USD

CY2019Q2

us-gaap

Net Investment Income

NetInvestmentIncome

285000000

USD

CY2020Q2

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

1853000000

USD

CY2019Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

1420000000

USD

CY2020Q2

us-gaap

Liabilities

53521000000

USD

CY2019Q4

us-gaap

Liabilities

45725000000

USD

CY2020Q2

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

USD

CY2019Q4

us-gaap

Commitments And Contingencies

CommitmentsAndContingencies

USD

CY2020Q2

us-gaap

Preferred Stock Value

PreferredStockValue

0

USD

CY2019Q4

us-gaap

Preferred Stock Value

PreferredStockValue

0

USD

CY2020Q2

us-gaap

Common Stock Value

CommonStockValue

3000000

USD

CY2019Q4

us-gaap

Common Stock Value

CommonStockValue

3000000

USD

CY2020Q2

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

9360000000

USD

CY2019Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

9448000000

USD

CY2020Q2

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

25346000000

USD

CY2019Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

22573000000

USD

CY2020Q2

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-254000000

USD

CY2019Q4

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-296000000

USD

CY2020Q2

us-gaap

Stockholders Equity

StockholdersEquity

34455000000

USD

CY2019Q4

us-gaap

Stockholders Equity

StockholdersEquity

31728000000

USD

CY2020Q2

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

87976000000

USD

CY2019Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

77453000000

USD

CY2020Q2

us-gaap

Premiums Earned Net

PremiumsEarnedNet

25092000000

USD

CY2019Q2

us-gaap

Premiums Earned Net

PremiumsEarnedNet

23501000000

USD

us-gaap

Premiums Earned Net

PremiumsEarnedNet

50609000000

USD

us-gaap

Premiums Earned Net

PremiumsEarnedNet

46344000000

USD

CY2020Q2

antm

Product Revenue

ProductRevenue

2543000000

USD

CY2019Q2

antm

Product Revenue

ProductRevenue

144000000

USD

CY2020Q2

antm

Operating Revenue

OperatingRevenue

29178000000

USD

CY2019Q2

antm

Operating Revenue

OperatingRevenue

25177000000

USD

antm

Operating Revenue

OperatingRevenue

58626000000

USD

antm

Operating Revenue

OperatingRevenue

49565000000

USD

CY2020Q2

us-gaap

Net Investment Income

NetInvestmentIncome

57000000

USD

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

6444000000

USD

CY2020Q2

us-gaap

Interest Expense

InterestExpense

201000000

USD

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

172000000

USD

CY2019Q2

us-gaap

Interest Expense

InterestExpense

184000000

USD

CY2020Q2

antm

Netrealizedlossesgainsonfinancialinstruments

18000000

USD

CY2019Q2

antm

Netrealizedlossesgainsonfinancialinstruments

11000000

USD

antm

Netrealizedlossesgainsonfinancialinstruments

-6000000

USD

antm

Netrealizedlossesgainsonfinancialinstruments

89000000

USD

CY2020Q2

antm

Impairmentlossesreversalsoninvestments

-6000000

USD

CY2019Q2

antm

Impairmentlossesreversalsoninvestments

9000000

USD

antm

Impairmentlossesreversalsoninvestments

95000000

USD

antm

Impairmentlossesreversalsoninvestments

22000000

USD

CY2020Q2

antm

Noncreditcomponentofimpairmentlossesoninvestmentsrecognizedinothercomprehensiveincomebeforetax

-5000000

USD

CY2019Q2

antm

Noncreditcomponentofimpairmentlossesoninvestmentsrecognizedinothercomprehensiveincomebeforetax

-2000000

USD

antm

Noncreditcomponentofimpairmentlossesoninvestmentsrecognizedinothercomprehensiveincomebeforetax

-49000000

USD

antm

Noncreditcomponentofimpairmentlossesoninvestmentsrecognizedinothercomprehensiveincomebeforetax

-5000000

USD

CY2020Q2

antm

Impairmentlossesreversalsrecognizedinearnings

-11000000

USD

CY2019Q2

antm

Impairmentlossesreversalsrecognizedinearnings

7000000

USD

antm

Impairmentlossesreversalsrecognizedinearnings

46000000

USD

antm

Impairmentlossesreversalsrecognizedinearnings

17000000

USD

CY2020Q2

us-gaap

Revenues

29264000000

USD

CY2019Q2

us-gaap

Revenues

25466000000

USD

us-gaap

Revenues

58885000000

USD

us-gaap

Revenues

50132000000

USD

CY2020Q2

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

19547000000

USD

CY2019Q2

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

20368000000

USD

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

41036000000

USD

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

39650000000

USD

CY2020Q2

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

2225000000

USD

CY2019Q2

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

98000000

USD

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

4209000000

USD

us-gaap

Cost Of Goods And Services Sold

CostOfGoodsAndServicesSold

98000000

USD

CY2020Q2

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

4046000000

USD

CY2019Q2

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

3278000000

USD

us-gaap

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

7827000000

USD

us-gaap

Interest Expense

InterestExpense

395000000

USD

us-gaap

Interest Expense

InterestExpense

371000000

USD

CY2020Q2

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

93000000

USD

CY2019Q2

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

85000000

USD

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

176000000

USD

CY2020Q2

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-3000000

USD

CY2019Q2

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

0

USD

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-4000000

USD

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

1000000

USD

CY2020Q2

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

26115000000

USD

CY2019Q2

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

24013000000

USD

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

53647000000

USD

us-gaap

Benefits Losses And Expenses

BenefitsLossesAndExpenses

46734000000

USD

CY2020Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

3149000000

USD

CY2019Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

1453000000

USD

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

5238000000

USD

us-gaap

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

3398000000

USD

CY2020Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

873000000

USD

CY2019Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

314000000

USD

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1439000000

USD

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

708000000

USD

CY2020Q2

us-gaap

Net Income Loss

NetIncomeLoss

2276000000

USD

CY2019Q2

us-gaap

Net Income Loss

NetIncomeLoss

1139000000

USD

us-gaap

Net Income Loss

NetIncomeLoss

3799000000

USD

us-gaap

Net Income Loss

NetIncomeLoss

2690000000

USD

CY2020Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

9.02

CY2019Q2

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

4.44

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

15.06

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

10.47

CY2020Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

8.91

CY2019Q2

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

4.36

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

14.85

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

10.28

CY2020Q2

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

0.95

CY2019Q2

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

0.80

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

1.90

us-gaap

Common Stock Dividends Per Share Declared

CommonStockDividendsPerShareDeclared

1.60

CY2020Q2

us-gaap

Net Income Loss

NetIncomeLoss

2276000000

USD

CY2019Q2

us-gaap

Net Income Loss

NetIncomeLoss

1139000000

USD

us-gaap

Net Income Loss

NetIncomeLoss

3799000000

USD

us-gaap

Net Income Loss

NetIncomeLoss

2690000000

USD

CY2020Q2

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

730000000

USD

CY2019Q2

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

238000000

USD

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

41000000

USD

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

595000000

USD

CY2020Q2

antm

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

10000000

USD

CY2019Q2

antm

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

-1000000

USD

antm

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

-22000000

USD

antm

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

-1000000

USD

CY2020Q2

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

3000000

USD

CY2019Q2

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

0

USD

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

6000000

USD

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

3000000

USD

CY2020Q2

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-10000000

USD

CY2019Q2

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-3000000

USD

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-17000000

USD

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-6000000

USD

CY2020Q2

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

1000000

USD

CY2019Q2

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

0

USD

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

0

USD

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

0

USD

CY2020Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

754000000

USD

CY2019Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

240000000

USD

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

42000000

USD

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

603000000

USD

CY2020Q2

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

3030000000

USD

CY2019Q2

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

1379000000

USD

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

3841000000

USD

us-gaap

Comprehensive Income Net Of Tax

ComprehensiveIncomeNetOfTax

3293000000

USD

us-gaap

Net Income Loss

NetIncomeLoss

3799000000

USD

us-gaap

Net Income Loss

NetIncomeLoss

2690000000

USD

antm

Netrealizedlossesgainsonfinancialinstruments

-6000000

USD

antm

Netrealizedlossesgainsonfinancialinstruments

89000000

USD

us-gaap

Depreciation Amortization And Accretion Net

DepreciationAmortizationAndAccretionNet

556000000

USD

us-gaap

Depreciation Amortization And Accretion Net

DepreciationAmortizationAndAccretionNet

586000000

USD

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

60000000

USD

us-gaap

Deferred Income Tax Expense Benefit

DeferredIncomeTaxExpenseBenefit

79000000

USD

us-gaap

Share Based Compensation

ShareBasedCompensation

134000000

USD

us-gaap

Share Based Compensation

ShareBasedCompensation

140000000

USD

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

313000000

USD

us-gaap

Increase Decrease In Receivables

IncreaseDecreaseInReceivables

589000000

USD

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

-24000000

USD

us-gaap

Increase Decrease In Trading Securities

IncreaseDecreaseInTradingSecurities

28000000

USD

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

486000000

USD

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

258000000

USD

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

1024000000

USD

us-gaap

Increase Decrease In Insurance Liabilities

IncreaseDecreaseInInsuranceLiabilities

1251000000

USD

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

-110000000

USD

us-gaap

Increase Decrease In Deferred Revenue

IncreaseDecreaseInDeferredRevenue

-2000000

USD

us-gaap

Increase Decrease In Accounts Payable And Other Operating Liabilities

IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities

1868000000

USD

us-gaap

Increase Decrease In Accounts Payable And Other Operating Liabilities

IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities

-383000000

USD

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

1313000000

USD

us-gaap

Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable

IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable

-286000000

USD

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

-150000000

USD

us-gaap

Increase Decrease In Other Operating Capital Net

IncreaseDecreaseInOtherOperatingCapitalNet

44000000

USD

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

8025000000

USD

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

3067000000

USD

us-gaap

Payments To Acquire Investments

PaymentsToAcquireInvestments

11135000000

USD

us-gaap

Payments To Acquire Investments

PaymentsToAcquireInvestments

11113000000

USD

antm

Proceedsfromsaleofequityandfixedmaturitysecurities

4724000000

USD

antm

Proceedsfromsaleofequityandfixedmaturitysecurities

8835000000

USD

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

1836000000

USD

us-gaap

Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities

ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities

894000000

USD

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

1906000000

USD

us-gaap

Payments To Acquire Businesses Net Of Cash Acquired

PaymentsToAcquireBusinessesNetOfCashAcquired

0

USD

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

437000000

USD

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

455000000

USD

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

800000000

USD

us-gaap

Payments For Proceeds From Other Investing Activities

PaymentsForProceedsFromOtherInvestingActivities

-22000000

USD

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-7718000000

USD

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-1817000000

USD

us-gaap

Proceeds From Repayments Of Commercial Paper

ProceedsFromRepaymentsOfCommercialPaper

-400000000

USD

us-gaap

Proceeds From Repayments Of Commercial Paper

ProceedsFromRepaymentsOfCommercialPaper

203000000

USD

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

2484000000

USD

us-gaap

Proceeds From Issuance Of Long Term Debt

ProceedsFromIssuanceOfLongTermDebt

0

USD

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

155000000

USD

us-gaap

Repayments Of Long Term Debt

RepaymentsOfLongTermDebt

73000000

USD

us-gaap

Proceeds From Short Term Debt

ProceedsFromShortTermDebt

820000000

USD

us-gaap

Proceeds From Short Term Debt

ProceedsFromShortTermDebt

4805000000

USD

us-gaap

Repayments Of Short Term Debt

RepaymentsOfShortTermDebt

1520000000

USD

us-gaap

Repayments Of Short Term Debt

RepaymentsOfShortTermDebt

4940000000

USD

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

584000000

USD

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

752000000

USD

us-gaap

Payments Of Dividends

PaymentsOfDividends

482000000

USD

us-gaap

Payments Of Dividends

PaymentsOfDividends

412000000

USD

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

92000000

USD

us-gaap

Proceeds From Stock Options Exercised

ProceedsFromStockOptionsExercised

100000000

USD

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

111000000

USD

us-gaap

Payments Related To Tax Withholding For Share Based Compensation

PaymentsRelatedToTaxWithholdingForShareBasedCompensation

80000000

USD

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

640000000

USD

us-gaap

Proceeds From Payments For Other Financing Activities

ProceedsFromPaymentsForOtherFinancingActivities

43000000

USD

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

784000000

USD

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-1106000000

USD

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

1091000000

USD

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

144000000

USD

CY2019Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

4937000000

USD

CY2018Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

3934000000

USD

CY2020Q2

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

6028000000

USD

CY2019Q2

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

4078000000

USD

CY2019Q4

us-gaap

Stockholders Equity

StockholdersEquity

31728000000

USD

CY2019Q4

us-gaap

Cumulative Effect Of New Accounting Principle In Period Of Adoption

CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

-35000000

USD

CY2019Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1

31693000000

USD

CY2020Q1

us-gaap

Net Income Loss

NetIncomeLoss

1523000000

USD

CY2020Q1

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

-712000000

USD

CY2020Q1

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

529000000

USD

CY2020Q1

us-gaap

Dividends Common Stock

DividendsCommonStock

243000000

USD

CY2020Q1

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

3000000

USD

CY2020Q1

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

-42000000

USD

CY2020Q1

us-gaap

Stockholders Equity

StockholdersEquity

31693000000

USD

CY2020Q2

us-gaap

Net Income Loss

NetIncomeLoss

2276000000

USD

CY2020Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

754000000

USD

CY2020Q2

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

55000000

USD

CY2020Q2

us-gaap

Dividends Common Stock

DividendsCommonStock

244000000

USD

CY2020Q2

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

113000000

USD

CY2020Q2

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

-82000000

USD

CY2020Q2

us-gaap

Stockholders Equity

StockholdersEquity

34455000000

USD

CY2018Q4

us-gaap

Stockholders Equity

StockholdersEquity

28541000000

USD

CY2018Q4

us-gaap

Cumulative Effect Of New Accounting Principle In Period Of Adoption

CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

26000000

USD

CY2018Q4

us-gaap

Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1

StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1

28567000000

USD

CY2019Q1

us-gaap

Net Income Loss

NetIncomeLoss

1551000000

USD

CY2019Q1

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

363000000

USD

CY2019Q1

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

294000000

USD

CY2019Q1

us-gaap

Dividends Common Stock

DividendsCommonStock

206000000

USD

CY2019Q1

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

69000000

USD

CY2019Q1

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

-52000000

USD

CY2019Q1

us-gaap

Stockholders Equity

StockholdersEquity

29998000000

USD

CY2019Q2

us-gaap

Net Income Loss

NetIncomeLoss

1139000000

USD

CY2019Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent

OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

240000000

USD

CY2019Q2

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

458000000

USD

CY2019Q2

us-gaap

Dividends Common Stock

DividendsCommonStock

208000000

USD

CY2019Q2

us-gaap

Stock Issued During Period Value Stock Options Exercised

StockIssuedDuringPeriodValueStockOptionsExercised

91000000

USD

CY2019Q2

us-gaap

Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments

AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments

-9000000

USD

CY2019Q2

us-gaap

Stockholders Equity

StockholdersEquity

30793000000

USD

us-gaap

Nature Of Operations

NatureOfOperations

<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">References to the terms “we,” “our,” “us” or “Anthem” used throughout these Notes to Consolidated Financial Statements refer to Anthem, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia, unless the context otherwise requires.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are one of the largest health benefits companies in the United States in terms of medical membership, serving greater than </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>42</span></span><span style="font-family:inherit;font-size:10pt;"> million </span><span style="font-family:inherit;font-size:10pt;">medical members through our affiliated health plans as of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">. We offer a broad spectrum of network-based managed care plans to Large Group, Small Group, Individual, Medicaid and Medicare markets. Our managed care plans include: Preferred Provider Organizations, or PPOs; Health Maintenance Organizations, or HMOs; Point-of-Service plans; traditional indemnity plans and other hybrid plans, including Consumer-Driven Health Plans; and hospital only and limited benefit products. In addition, we provide a broad array of managed care services to self-funded customers, including claims processing, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services. We provide an array of specialty and other insurance products and services such as pharmacy benefits management, or PBM, dental, vision, life and disability insurance benefits, radiology benefit management and analytics-driven personal healthcare. We also provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits, or FEHB, Program.</span></div><span style="font-family:inherit;font-size:10pt;">We are an independent licensee of the Blue Cross and Blue Shield Association, or BCBSA, an association of independent health benefit plans. </span><span style="font-family:inherit;font-size:10pt;">We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield, or BCBS, licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous </span><span style="font-family:inherit;font-size:10pt;">states across the country as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, Optimum HealthCare, Simply Healthcare, and/or Unicare. Also, in the second quarter of 2019, we began providing</span><span style="font-family:inherit;font-size:10pt;"> PBM services through our IngenioRx subsidiary. We are licensed to conduct insurance operations in all </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>50</span></span> states and the District of Columbia through our subsidiaries.

CY2020Q2

antm

Number Of Medical Members Served

NumberOfMedicalMembersServed

42000000

medical_member

CY2020Q2

antm

Number Of Counties In State Of Kansas Company Does Not Serve

NumberOfCountiesInStateOfKansasCompanyDoesNotServe

30

county

CY2020Q2

us-gaap

Number Of States In Which Entity Operates

NumberOfStatesInWhichEntityOperates

50

states

CY2020Q2

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

231000000

USD

CY2019Q4

us-gaap

Restricted Cash And Investments Current

RestrictedCashAndInvestmentsCurrent

215000000

USD

antm

Securities Lending Transactions Initial Collateral Percentage Value

SecuritiesLendingTransactionsInitialCollateralPercentageValue

1.02

CY2020Q2

us-gaap

Premiums Receivable Allowance For Doubtful Accounts

PremiumsReceivableAllowanceForDoubtfulAccounts

259000000

USD

CY2019Q4

us-gaap

Premiums Receivable Allowance For Doubtful Accounts

PremiumsReceivableAllowanceForDoubtfulAccounts

237000000

USD

CY2020Q2

antm

Selffunded Receivables Allowance For Doubtful Accounts

SelffundedReceivablesAllowanceForDoubtfulAccounts

52000000

USD

CY2019Q4

antm

Selffunded Receivables Allowance For Doubtful Accounts

SelffundedReceivablesAllowanceForDoubtfulAccounts

46000000

USD

CY2020Q2

us-gaap

Allowance For Doubtful Other Receivables Current

AllowanceForDoubtfulOtherReceivablesCurrent

321000000

USD

CY2019Q4

us-gaap

Allowance For Doubtful Other Receivables Current

AllowanceForDoubtfulOtherReceivablesCurrent

242000000

USD

CY2020Q1

us-gaap

Cumulative Effect Of New Accounting Principle In Period Of Adoption

CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

-35000000

USD

us-gaap

Description Of New Accounting Pronouncements Not Yet Adopted

DescriptionOfNewAccountingPronouncementsNotYetAdopted

<div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Guidance Not Yet Adopted: </span><span style="font-family:inherit;font-size:10pt;">In March 2020, the FASB issued Accounting Standards Update No. 2020-04, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="font-family:inherit;font-size:10pt;">, or ASU 2020-04. ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate, or LIBOR, or another reference rate expected to be discontinued because of the reference rate reform. The provisions must be applied at a Topic, Subtopic, or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. The provisions within ASU 2020-04 are available until December 31, 2022, when the reference rate replacement activity is expected to have been completed. We are currently evaluating the provisions within ASU 2020-04.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued Accounting Standards Update No. 2019-12, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,</span><span style="font-family:inherit;font-size:10pt;"> or ASU 2019-12. The amendments in ASU 2019-12 remove certain exceptions to the general principles in Accounting Standards Codification Topic 740. The amendments also clarify and amend existing guidance to improve consistent application. The amendments are effective for our annual reporting periods beginning after December 15, 2020, with early adoption permitted. The transition method (retrospective, modified retrospective, or prospective basis) related to the amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis. We are currently evaluating the effects the adoption of ASU 2019-12 will have on our consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued Accounting Standards Update No. 2018-14, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation—Retirement Benefits - Defined Benefit Plans—General (Subtopic 715-20): Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans</span><span style="font-family:inherit;font-size:10pt;">, or ASU 2018-14. The amendments in ASU 2018-14 eliminate, add, and modify certain disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The amendments are effective for our annual reporting periods beginning after December 15, 2020, with early adoption permitted. The guidance is to be applied on a retrospective basis to all periods presented. We are currently evaluating the effects the adoption of ASU 2018-14 will have on our disclosures.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued Accounting Standards Update No. 2018-12,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts, </span><span style="font-family:inherit;font-size:10pt;">or ASU 2018-12. The amendments in ASU 2018-12 make changes to a variety of areas to simplify or improve the existing recognition, measurement, presentation and disclosure requirements for long-duration contracts issued by an insurance entity. The amendments require insurers to annually review the assumptions they make about their policyholders and update the liabilities for future policy benefits if the assumptions change. The amendments also simplify the amortization of deferred contract acquisition costs and add new disclosure requirements about the assumptions insurers use to measure their liabilities and how they may affect future cash flows. The amendments in ASU 2018-12 will be effective for our interim and annual reporting periods beginning after December 15, 2021. The amendments related to the liability for future policy benefits for traditional and limited-payment contracts and deferred acquisition costs are to be applied to contracts in force as of the beginning of the earliest period presented, with an option to apply such amendments retrospectively with a cumulative-effect adjustment to the opening balance of retained earnings as of the earliest period presented. The amendments for market risk benefits are to be applied retrospectively. We are currently evaluating the effects the adoption of ASU 2018-12 will have on our consolidated financial position, results of operations, cash flows, and related disclosures.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no other new accounting pronouncements that were issued or became effective since the issuance of our </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position, results of operations or cash flows.</span></div>

CY2020Q2

antm

Netaccumulatedunrealizedgainslossesonavailableforsalefixedmaturitysecurities

713000000

USD

CY2019Q4

antm

Netaccumulatedunrealizedgainslossesonavailableforsalefixedmaturitysecurities

673000000

USD

CY2020Q1

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

51000000

USD

CY2020Q2

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded

DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded

10000000

USD

CY2020Q2

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss Securities Sold

DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold

-8000000

USD

CY2020Q2

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease

DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease

-29000000

USD

CY2020Q2

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

24000000

USD

CY2019Q4

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

0

USD

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded

DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded

61000000

USD

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss Securities Sold

DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold

-8000000

USD

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease

DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease

-29000000

USD

CY2020Q2

us-gaap

Debt Securities Available For Sale Allowance For Credit Loss

DebtSecuritiesAvailableForSaleAllowanceForCreditLoss

24000000

USD

CY2020Q2

us-gaap

Proceeds From Sale Of Available For Sale Securities

ProceedsFromSaleOfAvailableForSaleSecurities

2618000000

USD

CY2019Q2

us-gaap

Proceeds From Sale Of Available For Sale Securities

ProceedsFromSaleOfAvailableForSaleSecurities

1986000000

USD

us-gaap

Proceeds From Sale Of Available For Sale Securities

ProceedsFromSaleOfAvailableForSaleSecurities

4549000000

USD

us-gaap

Proceeds From Sale Of Available For Sale Securities

ProceedsFromSaleOfAvailableForSaleSecurities

3454000000

USD

CY2020Q2

us-gaap

Available For Sale Securities Gross Realized Gains

AvailableForSaleSecuritiesGrossRealizedGains

37000000

USD

CY2019Q2

us-gaap

Available For Sale Securities Gross Realized Gains

AvailableForSaleSecuritiesGrossRealizedGains

22000000

USD

us-gaap

Available For Sale Securities Gross Realized Gains

AvailableForSaleSecuritiesGrossRealizedGains

80000000

USD

us-gaap

Available For Sale Securities Gross Realized Gains

AvailableForSaleSecuritiesGrossRealizedGains

40000000

USD

CY2020Q2

us-gaap

Available For Sale Securities Gross Realized Losses

AvailableForSaleSecuritiesGrossRealizedLosses

50000000

USD

CY2019Q2

us-gaap

Available For Sale Securities Gross Realized Losses

AvailableForSaleSecuritiesGrossRealizedLosses

17000000

USD

us-gaap

Available For Sale Securities Gross Realized Losses

AvailableForSaleSecuritiesGrossRealizedLosses

70000000

USD

us-gaap

Available For Sale Securities Gross Realized Losses

AvailableForSaleSecuritiesGrossRealizedLosses

34000000

USD

CY2020Q2

antm

Equity Securities

EquitySecurities

3470000000

USD

CY2019Q4

antm

Equity Securities

EquitySecurities

1009000000

USD

CY2020Q2

us-gaap

Accrued Investment Income Receivable

AccruedInvestmentIncomeReceivable

182000000

USD

CY2019Q4

us-gaap

Accrued Investment Income Receivable

AccruedInvestmentIncomeReceivable

173000000

USD

CY2020Q2

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

1114000000

USD

CY2019Q4

us-gaap

Securities Loaned Fair Value Of Collateral

SecuritiesLoanedFairValueOfCollateral

351000000

USD

antm

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.02

CY2019

antm

Securities Lending Transactions Ratioof Fair Valueof Collateral Held To Securities On Loan

SecuritiesLendingTransactionsRatioofFairValueofCollateralHeldToSecuritiesOnLoan

1.03

CY2020Q2

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

3809000000

USD

CY2020Q2

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

1114000000

USD

CY2020Q2

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

30981000000

USD

CY2020Q2

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

0

USD

CY2019Q4

us-gaap

Cash And Cash Equivalents Fair Value Disclosure

CashAndCashEquivalentsFairValueDisclosure

2015000000

USD

CY2019Q4

us-gaap

Securities Held As Collateral At Fair Value

SecuritiesHeldAsCollateralAtFairValue

353000000

USD

CY2019Q4

us-gaap

Assets Fair Value Disclosure

AssetsFairValueDisclosure

23581000000

USD

CY2019Q4

us-gaap

Financial Liabilities Fair Value Disclosure

FinancialLiabilitiesFairValueDisclosure

1000000

USD

CY2020Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

405000000

USD

CY2020Q2

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

-9000000

USD

CY2020Q2

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss

-7000000

USD

CY2020Q2

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

17000000

USD

CY2020Q2

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales

14000000

USD

CY2020Q2

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements

9000000

USD

CY2020Q2

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

0

USD

CY2020Q2

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

0

USD

CY2020Q2

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

383000000

USD

CY2020Q2

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

-10000000

USD

CY2019Q1

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

614000000

USD

CY2019Q2

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

-1000000

USD

CY2019Q2

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss

0

USD

CY2019Q2

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

44000000

USD

CY2019Q2

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales

9000000

USD

CY2019Q2

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements

21000000

USD

CY2019Q2

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

0

USD

CY2019Q2

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

11000000

USD

CY2019Q2

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

616000000

USD

CY2019Q2

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

-2000000

USD

CY2019Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

397000000

USD

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

-17000000

USD

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss

-17000000

USD

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

54000000

USD

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales

26000000

USD

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements

21000000

USD

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

13000000

USD

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

0

USD

CY2020Q2

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

383000000

USD

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

-17000000

USD

CY2018Q4

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

623000000

USD

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

-4000000

USD

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Other Comprehensive Income Loss

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss

2000000

USD

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

86000000

USD

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales

31000000

USD

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements

43000000

USD

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

3000000

USD

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

20000000

USD

CY2019Q2

us-gaap

Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value

FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

616000000

USD

us-gaap

Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss

FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss

0

USD

CY2020Q2

us-gaap

Other Long Term Investments

OtherLongTermInvestments

4097000000

USD

CY2020Q2

us-gaap

Notes Payable

NotesPayable

24273000000

USD

CY2020Q2

us-gaap

Convertible Debt Noncurrent

ConvertibleDebtNoncurrent

426000000

USD

CY2019Q4

us-gaap

Other Long Term Investments

OtherLongTermInvestments

4258000000

USD

CY2019Q4

us-gaap

Short Term Borrowings

ShortTermBorrowings

700000000

USD

CY2019Q4

us-gaap

Commercial Paper

CommercialPaper

400000000

USD

CY2019Q4

us-gaap

Notes Payable

NotesPayable

20470000000

USD

CY2019Q4

us-gaap

Convertible Debt Noncurrent

ConvertibleDebtNoncurrent

904000000

USD

CY2020Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

873000000

USD

CY2019Q2

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

314000000

USD

CY2020Q2

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.277

CY2019Q2

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.216

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1439000000

USD

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

708000000

USD

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.275

us-gaap

Effective Income Tax Rate Continuing Operations

EffectiveIncomeTaxRateContinuingOperations

0.208

CY2020Q2

us-gaap

Accrued Income Taxes Current

AccruedIncomeTaxesCurrent

978000000

USD

CY2019Q4

us-gaap

Income Taxes Receivable

IncomeTaxesReceivable

335000000

USD

us-gaap

Defined Benefit Plan Contributions By Employer

DefinedBenefitPlanContributionsByEmployer

3000000

USD

us-gaap

Defined Benefit Plan Contributions By Employer

DefinedBenefitPlanContributionsByEmployer

0

USD

us-gaap

Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense

ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense

<div style="line-height:120%;padding-bottom:4px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Commercial</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">& Specialty</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Government</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross medical claims payable, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,608</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,647</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net medical claims payable, beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,025</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,589</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,614</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Business combinations and purchase adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>198</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>339</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net incurred medical claims:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,318</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,162</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>498</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,978</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior periods redundancies</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(374</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(326</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(700</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net incurred medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,944</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,836</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>498</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net payments attributable to:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current period medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,014</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,115</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>496</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,625</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior periods medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,218</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,823</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,041</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,938</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>496</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,666</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net medical claims payable, end of period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,737</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,628</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>200</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,565</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, end of period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross medical claims payable, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,799</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,656</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>200</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,655</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Activity in the Other segment resulted from our acquisition of Beacon.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the total of net incurred but not reported liabilities plus expected development on reported claims for the Commercial & Specialty Business was </span><span style="font-family:inherit;font-size:10pt;"><span>$74</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$358</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2,305</span></span><span style="font-family:inherit;font-size:10pt;"> for the claim years 2018 and prior, 2019 and 2020, respectively.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the total of net incurred but not reported liabilities plus expected development on reported claims for the Government Business was </span><span style="font-family:inherit;font-size:10pt;"><span>$80</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$360</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$6,188</span></span><span style="font-family:inherit;font-size:10pt;"> for the claim years 2018 and prior, 2019 and 2020, respectively.</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">June 30, 2020</span><span style="font-family:inherit;font-size:10pt;">, the total of net incurred but not reported liabilities plus expected development on reported claims for Other was </span><span style="font-family:inherit;font-size:10pt;"><span>$0</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$200</span></span><span style="font-family:inherit;font-size:10pt;"> for the claim years 2018 and prior, 2019 and 2020, respectively.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Commercial</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">& Specialty</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Government</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Business</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross medical claims payable, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,586</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,680</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,266</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net medical claims payable, beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,576</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,656</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net incurred medical claims:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,460</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,777</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,237</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior periods redundancies</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(182</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(232</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(414</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net incurred medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,545</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,823</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net payments attributable to:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current period medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,928</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,439</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,367</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior periods medical claims</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,081</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,101</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,182</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,009</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,540</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,549</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net medical claims payable, end of period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,845</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,661</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,506</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ceded medical claims payable, end of period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross medical claims payable, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,859</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,690</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,549</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div>

CY2019Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

8647000000

USD

CY2019Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

33000000

USD

CY2019Q4

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

8614000000

USD

CY2020Q2

antm

Liability For Unpaid Claims And Claims Adjustment Expense Purchase Adjustments

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePurchaseAdjustments

339000000

USD

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

39978000000

USD

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

700000000

USD

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

39278000000

USD

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

31625000000

USD

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

7041000000

USD

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

38666000000

USD

CY2020Q2

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

9565000000

USD

CY2020Q2

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

90000000

USD

CY2020Q2

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

9655000000

USD

CY2018Q4

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

7266000000

USD

CY2018Q4

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

34000000

USD

CY2018Q4

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

7232000000

USD

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense

38237000000

USD

us-gaap

Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense

SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense

414000000

USD

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

37823000000

USD

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1

30367000000

USD

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1

6182000000

USD

us-gaap

Payments For Losses And Loss Adjustment Expense

PaymentsForLossesAndLossAdjustmentExpense

36549000000

USD

CY2019Q2

antm

Shortdurationcontractliabilityforunpaidclaimsandadjustmentexpense Net

ShortdurationcontractliabilityforunpaidclaimsandadjustmentexpenseNet

8506000000

USD

CY2019Q2

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

43000000

USD

CY2019Q2

antm

Short Duration Contract Liability For Claims Adjustment Expense

ShortDurationContractLiabilityForClaimsAdjustmentExpense

8549000000

USD

CY2020Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

20530000000

USD

CY2020Q2

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

18748000000

USD

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

39278000000

USD

CY2020Q1

us-gaap

Supplementary Insurance Information Other Operating Expense

SupplementaryInsuranceInformationOtherOperatingExpense

959000000

USD

CY2020Q2

us-gaap

Supplementary Insurance Information Other Operating Expense

SupplementaryInsuranceInformationOtherOperatingExpense

799000000

USD

us-gaap

Supplementary Insurance Information Other Operating Expense

SupplementaryInsuranceInformationOtherOperatingExpense

1758000000

USD

CY2020Q1

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

21489000000

USD

CY2020Q2

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

19547000000

USD

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

41036000000

USD

CY2019Q1

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

18339000000

USD

CY2019Q2

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

19484000000

USD

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1

37823000000

USD

CY2019Q1

us-gaap

Supplementary Insurance Information Other Operating Expense

SupplementaryInsuranceInformationOtherOperatingExpense

943000000

USD

CY2019Q2

us-gaap

Supplementary Insurance Information Other Operating Expense

SupplementaryInsuranceInformationOtherOperatingExpense

884000000

USD

us-gaap

Supplementary Insurance Information Other Operating Expense

SupplementaryInsuranceInformationOtherOperatingExpense

1827000000

USD

CY2019Q1

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

19282000000

USD

CY2019Q2

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

20368000000

USD

us-gaap

Policyholder Benefits And Claims Incurred Net

PolicyholderBenefitsAndClaimsIncurredNet

39650000000

USD

CY2020Q2

us-gaap

Liability For Unpaid Claims And Claims Adjustment Expense Net

LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet

9565000000

USD

CY2020Q2

us-gaap

Reinsurance Recoverable For Unpaid Claims And Claims Adjustments

ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments

90000000

USD

CY2020Q2

us-gaap

Shortduration Insurance Contracts Liability For Unpaid Claims And Claim Adjustment Expense Other Reconciling Item

ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseOtherReconcilingItem

223000000

USD

CY2020Q2

us-gaap

Liability For Claims And Claims Adjustment Expense

LiabilityForClaimsAndClaimsAdjustmentExpense

9878000000

USD

CY2020Q2

antm

Gross Premium Tax Rate

GrossPremiumTaxRate

0.0235

CY2020Q2

antm

Merger Agreement Termination Fee

MergerAgreementTerminationFee

1850000000

USD

us-gaap

Long Term Purchase Commitment Amount

LongTermPurchaseCommitmentAmount

1700000000

USD

CY2020Q1

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2020-01-28

CY2020Q1

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2020-03-16

CY2020Q1

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2020-03-27

CY2020Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.95

CY2020Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

240000000

USD

CY2020Q2

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2020-04-28

CY2020Q2

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2020-06-10

CY2020Q2

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2020-06-25

CY2020Q2

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.95

CY2020Q2

us-gaap

Payments Of Dividends

PaymentsOfDividends

242000000

USD

CY2019Q1

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2019-01-29

CY2019Q1

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2019-03-18

CY2019Q1

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2019-03-29

CY2019Q1

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.80

CY2019Q1

us-gaap

Payments Of Dividends

PaymentsOfDividends

206000000

USD

CY2019Q2

us-gaap

Dividends Payable Date Declared Day Month And Year

DividendsPayableDateDeclaredDayMonthAndYear

2019-04-23

CY2019Q2

us-gaap

Dividends Payable Date Of Record Day Month And Year

DividendsPayableDateOfRecordDayMonthAndYear

2019-06-10

CY2019Q2

us-gaap

Dividend Payable Date To Be Paid Day Month And Year

DividendPayableDateToBePaidDayMonthAndYear

2019-06-25

CY2019Q2

us-gaap

Common Stock Dividends Per Share Cash Paid

CommonStockDividendsPerShareCashPaid

0.80

CY2019Q2

us-gaap

Payments Of Dividends

PaymentsOfDividends

206000000

USD

CY2017Q4

antm

Increase In Stock Repurchase Program Authorization

IncreaseInStockRepurchaseProgramAuthorization

5000000000

USD

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

2100000

shares

us-gaap

Stock Repurchased And Retired During Period Shares

StockRepurchasedAndRetiredDuringPeriodShares

2800000

shares

antm

Stock Repurchased And Retired During Period Average Price

StockRepurchasedAndRetiredDuringPeriodAveragePrice

273.72

antm

Stock Repurchased And Retired During Period Average Price

StockRepurchasedAndRetiredDuringPeriodAveragePrice

273.84

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

584000000

USD

us-gaap

Stock Repurchased And Retired During Period Value

StockRepurchasedAndRetiredDuringPeriodValue

752000000

USD

CY2020Q2

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

3208000000

USD

CY2019Q2

us-gaap

Stock Repurchase Program Remaining Authorized Repurchase Amount1

StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

4741000000

USD

CY2019Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

3100000

shares

CY2019Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

190.31

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

1000000.0

shares

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

271.33

us-gaap

Stock Issued During Period Shares Stock Options Exercised

StockIssuedDuringPeriodSharesStockOptionsExercised

500000

shares

us-gaap

Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

118.84

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

100000

shares

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

267.09

CY2020Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

3500000

shares

CY2020Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

221.84

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

P7Y29D

CY2020Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

182000000

USD

CY2020Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

1900000

shares

CY2020Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

176.59

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

P5Y6M3D

CY2020Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

175000000

USD

CY2019Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

1400000

shares

CY2019Q4

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

242.47

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

1300000

shares

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

272.14

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

1200000

shares

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

193.36

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

100000

shares

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

269.70

CY2020Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

1400000

shares

CY2020Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

271.77

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0130

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

0.0269

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.2600

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

0.2500

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.00350

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate

ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

0.00260

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P4Y3M18D

us-gaap

Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1

SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

P4Y4M24D

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

54.04

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

68.80

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

272.14

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

307.08

CY2020Q2

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

974000000

USD

CY2019Q2

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

626000000

USD

CY2020Q2

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

229000000

USD

CY2019Q2

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

60000000

USD

CY2020Q2

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax

745000000

USD

CY2019Q2

us-gaap

Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax

AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax

566000000

USD

CY2020Q2

antm

Available For Sale Securities Accumulated Other Comprehensive Income Net Deferred Tax Liability

AvailableForSaleSecuritiesAccumulatedOtherComprehensiveIncomeNetDeferredTaxLiability

-183000000

USD

CY2019Q2

antm

Available For Sale Securities Accumulated Other Comprehensive Income Net Deferred Tax Liability

AvailableForSaleSecuritiesAccumulatedOtherComprehensiveIncomeNetDeferredTaxLiability

-130000000

USD

CY2020Q2

us-gaap

Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

562000000

USD

CY2019Q2

us-gaap

Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

436000000

USD

CY2020Q2

antm

Accumulatedothercomprehensiveincomelossnoncreditcomponentofimpairmentsoninvestments

32000000

USD

CY2019Q2

antm

Accumulatedothercomprehensiveincomelossnoncreditcomponentofimpairmentsoninvestments

4000000

USD

CY2020Q2

antm

Non Credit Componentof Impairmentson Investments In Accumulated Other Comprehensive Income Deferred Tax Liability Asset

NonCreditComponentofImpairmentsonInvestmentsInAccumulatedOtherComprehensiveIncomeDeferredTaxLiabilityAsset

8000000

USD

CY2019Q2

antm

Non Credit Componentof Impairmentson Investments In Accumulated Other Comprehensive Income Deferred Tax Liability Asset

NonCreditComponentofImpairmentsonInvestmentsInAccumulatedOtherComprehensiveIncomeDeferredTaxLiabilityAsset

1000000

USD

CY2020Q2

antm

Accumulated Other Comprehensive Income Loss Non Credit Componentof Impairment Losson Investments Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNonCreditComponentofImpairmentLossonInvestmentsNetOfTax

24000000

USD

CY2019Q2

antm

Accumulated Other Comprehensive Income Loss Non Credit Componentof Impairment Losson Investments Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNonCreditComponentofImpairmentLossonInvestmentsNetOfTax

3000000

USD

antm

Aoci Cash Flow Hedge Unrealized Gain Loss Before Tax

AOCICashFlowHedgeUnrealizedGainLossBeforeTax

-323000000

USD

antm

Aoci Cash Flow Hedge Unrealized Gain Loss Before Tax

AOCICashFlowHedgeUnrealizedGainLossBeforeTax

-308000000

USD

CY2020Q2

antm

Cash Flow Hedging Instruments Accumulated Other Comprehensive Income Net Deferred Tax Asset

CashFlowHedgingInstrumentsAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset

67000000

USD

CY2019Q2

antm

Cash Flow Hedging Instruments Accumulated Other Comprehensive Income Net Deferred Tax Asset

CashFlowHedgingInstrumentsAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset

65000000

USD

CY2020Q2

us-gaap

Aoci Loss Cash Flow Hedge Cumulative Gain Loss After Tax

AociLossCashFlowHedgeCumulativeGainLossAfterTax

-256000000

USD

CY2019Q2

us-gaap

Aoci Loss Cash Flow Hedge Cumulative Gain Loss After Tax

AociLossCashFlowHedgeCumulativeGainLossAfterTax

-243000000

USD

CY2020Q2

us-gaap

Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax

-707000000

USD

CY2019Q2

us-gaap

Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax

-738000000

USD

CY2020Q2

us-gaap

Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax

1000000

USD

CY2019Q2

us-gaap

Defined Benefit Plan Accumulated Other Comprehensive Income Net Prior Service Cost Credit Before Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax

1000000

USD

CY2020Q2

antm

Defined Benefit Plan Accumulated Other Comprehensive Income Net Deferred Tax Asset

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset

-181000000

USD

CY2019Q2

antm

Defined Benefit Plan Accumulated Other Comprehensive Income Net Deferred Tax Asset

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetDeferredTaxAsset

-190000000

USD

CY2020Q2

antm

Defined Benefit Plan Accumulated Other Comprehensive Income Adjustments Net Of Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeAdjustmentsNetOfTax

527000000

USD

CY2019Q2

antm

Defined Benefit Plan Accumulated Other Comprehensive Income Adjustments Net Of Tax

DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeAdjustmentsNetOfTax

549000000

USD

CY2020Q2

antm

Deferred Net Actuarial Gain Loss Postretirement Benefits

DeferredNetActuarialGainLossPostretirementBenefits

-25000000

USD

CY2019Q2

antm

Deferred Net Actuarial Gain Loss Postretirement Benefits

DeferredNetActuarialGainLossPostretirementBenefits

-57000000

USD

CY2020Q2

antm

Deferred Prior Service Cost Credit Postretirement Benefit Plans

DeferredPriorServiceCostCreditPostretirementBenefitPlans

16000000

USD

CY2019Q2

antm

Deferred Prior Service Cost Credit Postretirement Benefit Plans

DeferredPriorServiceCostCreditPostretirementBenefitPlans

28000000

USD

CY2020Q2

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits

2000000

USD

CY2019Q2

us-gaap

Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits

DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits

7000000

USD

CY2020Q2

us-gaap

Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax

AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax

7000000

USD

CY2019Q2

us-gaap

Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax

AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax

22000000

USD

CY2020Q2

antm

Accumulated Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax

AccumulatedOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

-3000000

USD

CY2019Q2

antm

Accumulated Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax

AccumulatedOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax

-3000000

USD

CY2020Q2

us-gaap

Deferred Tax Assets Unrealized Currency Losses

DeferredTaxAssetsUnrealizedCurrencyLosses

1000000

USD

CY2019Q2

us-gaap

Deferred Tax Assets Unrealized Currency Losses

DeferredTaxAssetsUnrealizedCurrencyLosses

1000000

USD

CY2020Q2

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

-2000000

USD

CY2019Q2

us-gaap

Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax

AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

-2000000

USD

CY2020Q2

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-254000000

USD

CY2019Q2

us-gaap

Accumulated Other Comprehensive Income Loss Net Of Tax

AccumulatedOtherComprehensiveIncomeLossNetOfTax

-383000000

USD

CY2020Q2

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

741000000

USD

CY2019Q2

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

237000000

USD

CY2020Q2

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax

11000000

USD

CY2019Q2

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax

-1000000

USD

CY2020Q2

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

730000000

USD

CY2019Q2

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

238000000

USD

CY2020Q2

antm

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

10000000

USD

CY2019Q2

antm

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

-1000000

USD

CY2020Q2

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

3000000

USD

CY2019Q2

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

0

USD

CY2020Q2

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-10000000

USD

CY2019Q2

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-3000000

USD

CY2020Q2

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

1000000

USD

CY2019Q2

us-gaap

Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax

OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

0

USD

CY2020Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

754000000

USD

CY2019Q2

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

240000000

USD

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

33000000

USD

us-gaap

Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax

OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

586000000

USD

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax

-8000000

USD

us-gaap

Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax

OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax

-9000000

USD

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

41000000

USD

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

6000000

USD

us-gaap

Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

595000000

USD

antm

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

-22000000

USD

antm

Changeinnoncreditcomponentofimpairmentlossesoninvestmentsnetoftax

-1000000

USD

us-gaap

Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax

OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

3000000

USD

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-17000000

USD

us-gaap

Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax

OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

-6000000

USD

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

42000000

USD

us-gaap

Other Comprehensive Income Loss Net Of Tax

OtherComprehensiveIncomeLossNetOfTax

603000000

USD

CY2020Q2

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

252200000

shares

CY2019Q2

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

256700000

shares

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

252300000

shares

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

256900000

shares

CY2020Q2

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

3200000

shares

CY2019Q2

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

4300000

shares

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

3600000

shares

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

4700000

shares

CY2020Q2

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

255400000

shares

CY2019Q2

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

261000000.0

shares

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

255900000

shares

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

261600000

shares

CY2020Q2

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

1600000

shares

CY2019Q2

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

700000

shares

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

1300000

shares

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

500000

shares

CY2020Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

100000

shares

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

1300000

shares

antm

Potentially Dilutive Restricted Stock Units Contingent On Operating Results

PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults

200000

shares

CY2019Q2

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

0.0

shares

us-gaap

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period

ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

500000

shares

antm

Potentially Dilutive Restricted Stock Units Contingent On Operating Results

PotentiallyDilutiveRestrictedStockUnitsContingentOnOperatingResults

200000

shares

us-gaap

Number Of Reportable Segments

NumberOfReportableSegments

4

segment

CY2020Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

3360000000

USD

CY2019Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

1433000000

USD

us-gaap

Operating Income Loss

OperatingIncomeLoss

5554000000

USD

us-gaap

Operating Income Loss

OperatingIncomeLoss

3373000000

USD

CY2020Q2

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

29178000000

USD

CY2019Q2

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

25177000000

USD

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

58626000000

USD

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

49565000000

USD

CY2020Q2

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

29178000000

USD

CY2019Q2

antm

Operating Revenue

OperatingRevenue

25177000000

USD

us-gaap

Insurance Services Revenue

InsuranceServicesRevenue

58626000000

USD

antm

Operating Revenue

OperatingRevenue

49565000000

USD

CY2020Q2

us-gaap

Net Investment Income

NetInvestmentIncome

57000000

USD

CY2019Q2

us-gaap

Net Investment Income

NetInvestmentIncome

285000000

USD

us-gaap

Net Investment Income

NetInvestmentIncome

311000000

USD

us-gaap

Net Investment Income

NetInvestmentIncome

495000000

USD

CY2020Q2

antm

Netrealizedlossesgainsonfinancialinstruments

18000000

USD

CY2019Q2

antm

Netrealizedlossesgainsonfinancialinstruments

11000000

USD

antm

Netrealizedlossesgainsonfinancialinstruments

-6000000

USD

antm

Netrealizedlossesgainsonfinancialinstruments

89000000

USD

CY2020Q2

antm

Impairmentlossesreversalsrecognizedinearnings

-11000000

USD

CY2019Q2

antm

Impairmentlossesreversalsrecognizedinearnings

7000000

USD

antm

Impairmentlossesreversalsrecognizedinearnings

46000000

USD

antm

Impairmentlossesreversalsrecognizedinearnings

17000000

USD

CY2020Q2

us-gaap

Revenues

29264000000

USD

CY2019Q2

us-gaap

Revenues

25466000000

USD

us-gaap

Revenues

58885000000

USD

us-gaap

Revenues

50132000000

USD

antm

Netrealizedlossesgainsonfinancialinstruments

89000000

USD

CY2020Q2

antm

Impairmentlossesreversalsrecognizedinearnings

-11000000

USD

CY2019Q2

antm

Impairmentlossesreversalsrecognizedinearnings

7000000

USD

antm

Impairmentlossesreversalsrecognizedinearnings

46000000

USD

antm

Impairmentlossesreversalsrecognizedinearnings

17000000

USD

CY2020Q2

antm

Netrealizedlossesgainsonfinancialinstruments

18000000

USD

CY2019Q2

antm

Netrealizedlossesgainsonfinancialinstruments

11000000

USD

CY2020Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

3360000000

USD

CY2019Q2

us-gaap

Operating Income Loss

OperatingIncomeLoss

1433000000

USD

us-gaap

Operating Income Loss

OperatingIncomeLoss

5554000000

USD

us-gaap

Operating Income Loss

OperatingIncomeLoss

3373000000

USD

CY2020Q2

us-gaap

Net Investment Income

NetInvestmentIncome

57000000

USD

CY2019Q2

us-gaap

Net Investment Income

NetInvestmentIncome

285000000

USD

us-gaap

Net Investment Income

NetInvestmentIncome

311000000

USD

us-gaap

Net Investment Income

NetInvestmentIncome

495000000

USD

antm

Netrealizedlossesgainsonfinancialinstruments

-6000000

USD

CY2020Q2

us-gaap

Interest Expense

InterestExpense

201000000

USD

CY2019Q2

us-gaap

Interest Expense

InterestExpense

184000000

USD

us-gaap

Interest Expense

InterestExpense

395000000

USD

us-gaap

Interest Expense

InterestExpense

371000000

USD

CY2020Q2

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

93000000

USD

CY2019Q2

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

85000000

USD

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

176000000

USD

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

172000000

USD

CY2020Q2

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-3000000

USD

CY2019Q2

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

0

USD

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

-4000000

USD

us-gaap

Gains Losses On Extinguishment Of Debt

GainsLossesOnExtinguishmentOfDebt

1000000

USD

CY2020Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

3149000000

USD

CY2019Q2

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

1453000000

USD

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

5238000000

USD

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

3398000000

USD

CY2020Q2

us-gaap

Operating Lease Cost

OperatingLeaseCost

59000000

USD

CY2019Q2

us-gaap

Operating Lease Cost

OperatingLeaseCost

45000000

USD

us-gaap

Operating Lease Cost

OperatingLeaseCost

106000000

USD

us-gaap

Operating Lease Cost

OperatingLeaseCost

90000000

USD

CY2020Q2

us-gaap

Short Term Lease Cost

ShortTermLeaseCost

14000000

USD

CY2019Q2

us-gaap

Short Term Lease Cost

ShortTermLeaseCost

12000000

USD

us-gaap

Short Term Lease Cost

ShortTermLeaseCost

27000000

USD

us-gaap

Short Term Lease Cost

ShortTermLeaseCost

24000000

USD

CY2020Q2

us-gaap

Sublease Income

SubleaseIncome

4000000

USD

CY2019Q2

us-gaap

Sublease Income

SubleaseIncome

4000000

USD

us-gaap

Sublease Income

SubleaseIncome

7000000

USD

us-gaap

Sublease Income

SubleaseIncome

8000000

USD

CY2020Q2

us-gaap

Lease Cost

LeaseCost

69000000

USD

CY2019Q2

us-gaap

Lease Cost

LeaseCost

53000000

USD

us-gaap

Lease Cost

LeaseCost

126000000

USD

us-gaap

Lease Cost

LeaseCost

106000000

USD

CY2020Q2

us-gaap

Operating Lease Payments

OperatingLeasePayments

46000000

USD

CY2019Q2

us-gaap

Operating Lease Payments

OperatingLeasePayments

44000000

USD

us-gaap

Operating Lease Payments

OperatingLeasePayments

90000000

USD

us-gaap

Operating Lease Payments

OperatingLeasePayments

89000000

USD

CY2020Q2

us-gaap

Right Of Use Asset Obtained In Exchange For Operating Lease Liability

RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

33000000

USD

CY2019Q2

us-gaap

Right Of Use Asset Obtained In Exchange For Operating Lease Liability

RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

0

USD

us-gaap

Right Of Use Asset Obtained In Exchange For Operating Lease Liability

RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

356000000

USD

us-gaap

Right Of Use Asset Obtained In Exchange For Operating Lease Liability

RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

0

USD

CY2020Q2

us-gaap

Operating Lease Weighted Average Remaining Lease Term1

OperatingLeaseWeightedAverageRemainingLeaseTerm1

P7Y

CY2019Q2

us-gaap

Operating Lease Weighted Average Remaining Lease Term1

OperatingLeaseWeightedAverageRemainingLeaseTerm1

P7Y

CY2020Q2

us-gaap

Operating Lease Weighted Average Remaining Lease Term1

OperatingLeaseWeightedAverageRemainingLeaseTerm1

P7Y

CY2019Q2

us-gaap

Operating Lease Weighted Average Remaining Lease Term1

OperatingLeaseWeightedAverageRemainingLeaseTerm1

P7Y

CY2020Q2

us-gaap

Operating Lease Weighted Average Discount Rate Percent

OperatingLeaseWeightedAverageDiscountRatePercent

0.0345

CY2019Q2

us-gaap

Operating Lease Weighted Average Discount Rate Percent

OperatingLeaseWeightedAverageDiscountRatePercent

0.0390

CY2020Q2

us-gaap

Operating Lease Weighted Average Discount Rate Percent

OperatingLeaseWeightedAverageDiscountRatePercent

0.0345

CY2019Q2

us-gaap

Operating Lease Weighted Average Discount Rate Percent

OperatingLeaseWeightedAverageDiscountRatePercent

0.0390

CY2020Q2

us-gaap

Lessee Operating Lease Liability Payments Remainder Of Fiscal Year

LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear

99000000

USD

CY2020Q2

us-gaap

Lessee Operating Lease Liability Payments Due Year Two

LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

192000000

USD

CY2020Q2

us-gaap

Lessee Operating Lease Liability Payments Due Year Three

LesseeOperatingLeaseLiabilityPaymentsDueYearThree

176000000

USD

CY2020Q2

us-gaap

Lessee Operating Lease Liability Payments Due Year Four

LesseeOperatingLeaseLiabilityPaymentsDueYearFour

153000000

USD

CY2020Q2

us-gaap

Lessee Operating Lease Liability Payments Due Year Five

LesseeOperatingLeaseLiabilityPaymentsDueYearFive

123000000

USD

CY2020Q2

us-gaap

Lessee Operating Lease Liability Payments Due After Year Five

LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive

313000000

USD

CY2020Q2

us-gaap

Lessee Operating Lease Liability Payments Due

LesseeOperatingLeaseLiabilityPaymentsDue

1056000000

USD

CY2020Q2

us-gaap

Lessee Operating Lease Liability Undiscounted Excess Amount

LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

48000000

USD

CY2020Q2

us-gaap

Operating Lease Liability

OperatingLeaseLiability

1008000000

USD

CY2020Q2

us-gaap

Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1

LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1

P12Y

us-gaap

Lessee Operating Lease Lease Not Yet Commenced Description

LesseeOperatingLeaseLeaseNotYetCommencedDescription

are expected to commence on various dates during 2020 and 2021 when the construction is complete and we take possession of the buildings

CY2020Q2

antm

Lessee Operating Lease Lease Not Yet Commenced Expense

LesseeOperatingLeaseLeaseNotYetCommencedExpense

138000000

USD

Name	View Source	Status
0001156039-20-000070-index-headers.html	Edgar Link	pending
0001156039-20-000070-index.html	Edgar Link	pending
0001156039-20-000070.txt	Edgar Link	pending
0001156039-20-000070-xbrl.zip	Edgar Link	pending
antm-20200630.xsd	Edgar Link	pending
antm-20200630_cal.xml	Edgar Link	unprocessable
antm-20200630_def.xml	Edgar Link	unprocessable
antm-20200630_lab.xml	Edgar Link	unprocessable
antm-20200630_pre.xml	Edgar Link	unprocessable
antm-2020630x10q.htm	Edgar Link	pending
antm-2020630x10q_htm.xml	Edgar Link	completed
exhibit311-202063010qq.htm	Edgar Link	pending
exhibit312-202063010qq.htm	Edgar Link	pending
exhibit321-202063010qq.htm	Edgar Link	pending
exhibit322-202063010qq.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELV
Elevance Health, Inc. Stock $elv

2020 Q2 Form 10-Q Financial Statement

#000115603920000070 Filed on July 29, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELV Elevance Health, Inc. Stock $elv

2020 Q2 Form 10-Q Financial Statement

#000115603920000070 Filed on July 29, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELV
Elevance Health, Inc. Stock $elv